DBV Technologies (NASDAQ:DBVT) Major Shareholder Sells $10,073,401.50 in Stock

DBV Technologies S.A. (NASDAQ:DBVT) major shareholder Bpifrance Epic sold 2,076,990 shares of the company’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $4.85, for a total transaction of $10,073,401.50. Following the completion of the transaction, the insider owned 8,595,472 shares in the company, valued at approximately $41,688,039.20. The trade was a 19.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Bpifrance Epic also recently made the following trade(s):

• On Thursday, December 18th, Bpifrance Epic sold 1,292,103 shares of DBV Technologies stock. The shares were sold at an average price of $4.19, for a total transaction of $5,413,911.57.

DBV Technologies Stock Up 5.8%

Shares of NASDAQ DBVT traded up $1.24 during midday trading on Friday, hitting $22.76. The stock had a trading volume of 431,282 shares, compared to its average volume of 223,539. The business’s 50 day moving average is $15.23 and its 200-day moving average is $11.72. DBV Technologies S.A. has a 52 week low of $2.92 and a 52 week high of $26.18. The company has a market cap of $914.04 million, a P/E ratio of -4.40 and a beta of -1.10.

DBV Technologies News Roundup

Here are the key news stories impacting DBV Technologies this week:

• Positive Sentiment: DBV reported a Phase III win in peanut allergy — a major clinical validation that materially de-risks the company’s lead program and supports future commercial potential. Vitesse finesse pays off: DBV wins in peanut allergy phase III
• Positive Sentiment: HC Wainwright materially raised EPS forecasts for FY2027–FY2029 (notably FY2029 to +$2.25), signaling stronger expected profitability and helping re-rate DBV’s outlook. This analyst revision is a key driver behind buying interest. HC Wainwright Expects Stronger Earnings for DBV Technologies
• Positive Sentiment: Broader broker reaction has been favorable: DBV was given an average “Moderate Buy” and firms (including Citizens JMP) published bullish commentary and price targets, which helped push the stock to a 1‑year high. Those external endorsements amplify the impact of the trial and estimate upgrades. DBV Technologies S.A. (NASDAQ:DBVT) Given Average Recommendation of “Moderate Buy” by Brokerages Citizens Jmp Forecasts Strong Price Appreciation for DBV Technologies (NASDAQ:DBVT) Stock DBV Technologies (NASDAQ:DBVT) Hits New 1-Year High Following Analyst Upgrade
• Neutral Sentiment: Consensus still shows a deeply negative current-year EPS (around -$7.05), so near-term earnings remain weak; the market reaction reflects re‑rating toward future upside rather than immediate profitability.
• Negative Sentiment: Lifesci Capital trimmed FY2026 EPS estimates (to about -$1.95), a reminder that some analysts remain cautious on near-term cash flow and runway — this is a modest headwind compared with the more prominent positive news.

Institutional Investors Weigh In On DBV Technologies

Large investors have recently made changes to their positions in the company. Millennium Management LLC increased its holdings in DBV Technologies by 26.1% in the 3rd quarter. Millennium Management LLC now owns 337,863 shares of the company’s stock worth $3,379,000 after acquiring an additional 69,849 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of DBV Technologies in the third quarter worth approximately $220,000. Two Sigma Investments LP bought a new position in shares of DBV Technologies in the third quarter worth approximately $167,000. DLD Asset Management LP purchased a new stake in shares of DBV Technologies in the third quarter worth $250,000. Finally, Artisan Partners Limited Partnership bought a new stake in shares of DBV Technologies during the 3rd quarter valued at $519,000. 71.74% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

DBVT has been the subject of a number of research analyst reports. Cantor Fitzgerald set a $48.00 target price on DBV Technologies in a report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DBV Technologies in a research report on Monday, December 8th. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a research report on Wednesday. Citizens Jmp raised their price target on shares of DBV Technologies from $21.00 to $45.00 and gave the company a “market outperform” rating in a report on Wednesday. Finally, HC Wainwright set a $40.00 price objective on shares of DBV Technologies in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $35.38.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.